Best Agrolife Limited (BESTAGRO) Fair Value & Analysis
Basic Materials · IN · Market cap ₹5.5B
Fair value as of: Jun 29, 2026
Analysis
Best Agrolife Limited (BESTAGRO) currently trades at ₹15.58, while our model-based Fair Value estimate is ₹11.86 — implying the stock looks roughly 23.9% overvalued today. We read business quality at 97/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Best Agrolife Limited engages in the manufacture and sale of agrochemical products in India and internationally. The company offers insecticides, herbicides, fungicides, public-health, and plant growth regulator (PGR) products in the form of technical, intermediates, and novel formulations. The company also offers NEMAGENTM, a novel insecticide combination; DEFENDERTM, a dual-action insecticide + fungicide in WG form; ORISULAMTM, a breakthrough herbicidal composition (GR formulation); and WARDEN EXTRATM, a ternary SC formulation offering broad-spectrum control. It offers its products through a network of distributors. The company was formerly known as Sahyog Multibase Limited and changed its name to Best Agrolife Limited in October 2019. Best Agrolife Limited was incorporated in 1992 and is based in New Delhi, India.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Best Agrolife Limited (BESTAGRO) undervalued?
What is the fair value of BESTAGRO?
What is the quality score of BESTAGRO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.